These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 26267736

  • 1. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP, Fanucci KA, Saraiya A, Volf E, Au SC, Argobi Y, Mansfield R, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
    [Abstract] [Full Text] [Related]

  • 2. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C, Plotnikova N, Au SC, Sorensen EP, Gottlieb A.
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [Abstract] [Full Text] [Related]

  • 3. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C, Creighton-Smith M, Sorensen EP, Dumont N, Gottlieb AB.
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [Abstract] [Full Text] [Related]

  • 4. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N, Noda S, Taniguchi T, Adachi M.
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [Abstract] [Full Text] [Related]

  • 5. Ustekinumab in patients previously treated with TNFα inhibitors: a real-life study.
    Pinheiro RR, Duarte B, Ferreira A, Cabete J.
    Eur J Dermatol; 2018 Feb 01; 28(1):89-91. PubMed ID: 29400282
    [No Abstract] [Full Text] [Related]

  • 6. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
    Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P.
    J Am Acad Dermatol; 2017 Jan 01; 76(1):81-90. PubMed ID: 27894789
    [Abstract] [Full Text] [Related]

  • 7. The Association between Clinical Response to Ustekinumab and Immunogenicity to Ustekinumab and Prior Adalimumab.
    Chiu HY, Chu TW, Cheng YP, Tsai TF.
    PLoS One; 2015 Jan 01; 10(11):e0142930. PubMed ID: 26566272
    [Abstract] [Full Text] [Related]

  • 8. Biologic drug survival in Israeli psoriasis patients.
    Shalom G, Cohen AD, Ziv M, Eran CB, Feldhamer I, Freud T, Berman E, Oren S, Hodak E, Pavlovsky L.
    J Am Acad Dermatol; 2017 Apr 01; 76(4):662-669.e1. PubMed ID: 28038888
    [Abstract] [Full Text] [Related]

  • 9. Treatment efficacy and patient satisfaction of ustekinumab compared with tumor necrosis factor-alpha inhibitors in Chinese patients with moderate-to-severe psoriasis: a real-world study.
    Guo B, Jin X, Fan L, Zhang Y, Xu B, Yang T.
    J Dermatolog Treat; 2024 Dec 01; 35(1):2405554. PubMed ID: 39299697
    [Abstract] [Full Text] [Related]

  • 10. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O, Rodríguez-Soria VJ, Romero-Jiménez RM, Suárez R.
    Actas Dermosifiliogr; 2015 Sep 01; 106(7):569-77. PubMed ID: 25935194
    [Abstract] [Full Text] [Related]

  • 11. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C, Marshman G, Grillo M, Stanford T.
    Australas J Dermatol; 2016 May 01; 57(2):137-40. PubMed ID: 25754697
    [Abstract] [Full Text] [Related]

  • 12. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
    Van Lümig PP, Lecluse LL, Driessen RJ, Spuls PI, Boezeman JB, van de Kerkhof PC, De Jong EM.
    Br J Dermatol; 2010 Oct 01; 163(4):838-46. PubMed ID: 20649798
    [Abstract] [Full Text] [Related]

  • 13. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
    Talamonti M, Galluzzo M, Bernardini N, Caldarola G, Persechino S, Cantoresi F, Egan CG, Potenza C, Peris K, Bianchi L.
    J Eur Acad Dermatol Venereol; 2018 Oct 01; 32(10):1737-1744. PubMed ID: 29776016
    [Abstract] [Full Text] [Related]

  • 14. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R, Gál B, Gaál M, Kiss M, Kemény L, Gyulai R.
    J Dermatol; 2016 Sep 01; 43(9):1018-23. PubMed ID: 26892625
    [Abstract] [Full Text] [Related]

  • 15. Effects of tumor necrosis factor-α, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis.
    Takamura S, Takahashi A, Inoue Y, Teraki Y.
    J Dermatol; 2018 Sep 01; 45(9):1130-1134. PubMed ID: 30004583
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of sequential use of biologics in the treatment of moderate to severe psoriasis in real world Canadian academic clinical practice: A cohort study.
    Qiang JK, Shahbaz A, Kim W, Marinas J, Greaves S, Yeung J.
    J Am Acad Dermatol; 2016 Jan 01; 74(1):176-7. PubMed ID: 26702799
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
    Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, Guzzo C, Xia Y, Zhou B, Li S, Dooley LT, Goldstein NH, Menter A, ACCEPT Study Group.
    N Engl J Med; 2010 Jan 14; 362(2):118-28. PubMed ID: 20071701
    [Abstract] [Full Text] [Related]

  • 18. Ustekinumab Demonstrates Lower Uveitis Risk in Moderate to Severe Psoriasis Patients Compared with Tumor Necrosis Factor-α Inhibitors.
    Bang CH, Oh HJ, Kim YH, Jung JH, Lee JH, Park YM, Han JH.
    Acta Derm Venereol; 2024 Sep 09; 104():adv34206. PubMed ID: 39248291
    [No Abstract] [Full Text] [Related]

  • 19. Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis.
    Yanaba K, Umezawa Y, Honda H, Sato R, Chiba M, Kikuchi S, Asahina A, Nakagawa H.
    J Dermatol; 2016 Apr 09; 43(4):443-4. PubMed ID: 26662275
    [No Abstract] [Full Text] [Related]

  • 20. The Role of Biologic Therapies in Dermatology.
    Fathi R, Armstrong AW.
    Med Clin North Am; 2015 Nov 09; 99(6):1183-94. PubMed ID: 26476247
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.